Results 231 to 240 of about 247,348 (342)

Effects of protease inhibitors in experimental septic shock [PDF]

, 1992
Fink, Edwin, Hoffmann, H., Siebeck, Matthias, Spannagl, Michael   +3 more
core  

Point to ponder while prescribing phenytoin sodium infusion in septic shock patients: A case-based discussion

, 2016
Habib Md Reazaul Karim, Ghazal Ahmed, Mohammad Yunus, Prithwis Bhattacharyya   +3 more
openalex   +1 more source

Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter Study

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to compare differences in clinical response, drug survival, and adverse event rates between anakinra and canakinumab in VEXAS (vacuoles, E1 enzyme, X‐linked, autoinflammatory, somatic) syndrome. Methods This multicenter international study includes patients with VEXAS from France, Israel, and Italy treated with ...
Tali Eviatar, Dafne Capelusnik, Corrado Campochiaro, Valentin Lacombe, Vincent Jachiet, Michael Zisapel, Iftach Sagy, Oshrat E. Tayer‐Shifman, David Ozeri, Shaye Kivity, Alessandro Tomelleri, Benjamin Terrier, Hagit Peleg, Thibault Comont, Karim Sacre, Pascal Woaye‐Hune, Laurent Arnaud, Estibaliz Lazaro, Vincent Grobost, Francois Lifermann, Maxime Samson, Samuel Ardois, Alice Garnier, Alexandre Maria, Alain Cantagrel, Aurore Meyer, Jean‐David Bouaziz, Mael Heiblig, Lorenzo Dagna, Elisa Diral, Olivier Kosmider, Ori Elkayam, Jérôme Hadjadj, Sophie Georgin‐Lavialle, Olivier Fain, Arsene Mekinian   +35 more
wiley   +1 more source

Exploring vasopressin use in septic shock: a retrospective cohort study from Türkiye (VASCO-TURK). [PDF]

BMC Anesthesiol
Küçük AO, Hocek AB, Aydın D, Acar B, Pehlivanlar E, Pehlivanlar Küçük M.   +5 more
europepmc   +1 more source

Identification of histone deacetylase inhibitor targeting type I interferon and B‐cell abnormalities in systemic lupus erythematosus

Arthritis &Rheumatology, Accepted Article.
Objective Systemic lupus erythematosus (SLE) is characterized by increased type I interferon (IFN‐I) and autoantibody production. This study aimed to identify drugs that can inhibit both IFN‐I and autoantibody production. Methods We identified an inhibitor of IFN‐I production from a chemical library.
Takehiro Hirayama, Hachiro Konaka, Yasuhiro Kato, Takayuki Shibahara, Chisato Nishizawa, Kohei Tsujimoto, JeongHoon Park, Eri Itotagawa, Tatsunori Jo, Masayuki Nishide, Sumiyuki Nishida, Yoshihito Shima, Masashi Narazaki, Wataru Aoki, Ken J Ishii, Hyota Takamatsu, Atsushi Kumanogoh   +16 more
wiley   +1 more source

The PFI-index according to Aasen for prognosis and course of polytraumatized patients [PDF]

, 1988
Baumgartner, I., Duswald, Karl-Heimo, Jochum, Marianne, Nast-Kolb, Dieter, Redl, H., Schlag, G., Schweiberer, Leonhard, Waydhas, Christian   +7 more
core  

Automated screening of natural language in electronic health records for the diagnosis septic shock is feasible and outperforms an approach based on explicit administrative codes

, 2020
Colpaert, Kirsten, De Bus, Liesbet, Decruyenaere, Johan, Depuydt, Pieter, Vermassen, Joris   +4 more
core   +1 more source

Immunophenotyping of septic shock patients with endotheliopathy: focus on monocyte subtypes and Immune regulatory molecules. [PDF]

Front Immunol
Al-Haidar S, Schønemann-Lund M, Gybel-Brask M, Stensballe J, Andresen L, Johansson PI, Bestle MH, Skov S.   +7 more
europepmc   +1 more source

A Case of Septic Shock due to Pneumonia caused by Klebsiella pneumoniae

, 1989
Masumi Baba, Yasuo Ono, Yuichirou Ueda, Toshiaki Haga, Norio Nozue, Hajime Nishiya, O Kunii   +6 more
openalex   +2 more sources

Risk factors for relapse in ANCA‐associated vasculitis among patients with relapse after induction of remission with rituximab

Arthritis &Rheumatology, Accepted Article.
Objective To determine risk factors for relapse of ANCA‐associated vasculitis (AAV) after re‐induction of remission with rituximab and discontinuation of maintenance therapy. Methods This is a post‐hoc analysis of the RITAZAREM clinical trial. Patients 15 years or older with AAV and a positive test for anti‐proteinase‐3 (PR3‐) or anti‐myeloperoxidase ...
Ellen Romich, Joshua F. Baker, Thomas R. Riley IV, Ian Green, Rennie L. Rhee, Carol A. McAlear, Ulrich Specks, Rona M. Smith, David R. Jayne, Peter A. Merkel, for the RITAZAREM Investigators   +10 more
wiley   +1 more source